Raptor Says Phase 2b Trial For NAFLD In Children Met Enrollment Target

(RTTNews) - Raptor Pharmaceutical Corp. (RPTP) Monday announced that its Phase 2b clinical trial, to evaluate safety and potential efficacy of RP103 delayed-release cysteamine bitartrate as a prospective treatment of non-alcoholic fatty liver disease, or NAFLD, in children, has met its enrollment target.

Raptor is conducting this trial in cooperation with the National Institute of Diabetes and Digestive and Kidney Diseases, part of the National Institutes of Health, under a Cooperative Research and Development Agreement.

The trial, called Cysteamine Bitartrate Delayed-Release for the Treatment of Non-alcoholic Fatty Liver Disease in Children, or CyNCh, enrolled 160 pediatric participants at ten U.S. centers in the NIDDK-sponsored NASH Clinical Research Network. NIDDK and Raptor are sharing development costs related to the CyNCh study.

Full results from the Phase 2b CyNCh trial are expected in the first half of 2015.